Status:
WITHDRAWN
A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will evaluate the effect of inhibitors, at steady state, on the drug levels, safety, and tolerability of BMS-986235 when taken by healthy participants. The inhibitors to be utilized in this...
Eligibility Criteria
Inclusion
- Body mass index of 18.0 kg/m2 to 32.0 kg/m2, inclusive, at screening.
- Males and females must agree to follow specific methods of contraception, if applicable.
- Healthy participants, as determined by no clinically significant deviation from normal in physical examination, ECGs, and clinical laboratory determinations, and no significant findings in medical history.
Exclusion
- Women of childbearing potential (WOCBP), women who are pregnant or breastfeeding
- Inability to tolerate oral medication
- Known previous exposure to BMS-986235.
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 8 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04464577
Start Date
April 1 2021
End Date
June 8 2021
Last Update
March 25 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Lenexa, Kansas, United States, 66219
2
Local Institution
Salt Lake City, Utah, United States, 84124